[Skip to Navigation]
Comment & Response
October 14, 2021

Association Between Mortality and Anti–Vascular Endothelial Growth Factor Treatment in Patients With Age-Related Macular Degeneration

Author Affiliations
  • 1Helsinki Retina Research Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland
  • 2Hygeia Clinic, Gdańsk, Poland
  • 3Hebrew University of Jerusalem, Jerusalem, Israel
  • 4Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland
JAMA Ophthalmol. 2021;139(11):1246-1247. doi:10.1001/jamaophthalmol.2021.4079

To the Editor We have read the article by Ngo Ntjam et al,1 in which the authors carried out a systematic review and meta-analysis to analyze major adverse cardiovascular events (MACEs) associated with anti–vascular endothelial growth factor (VEGF) injections. Only randomized clinical trials were included in the analysis, and the study concluded that intravitreal anti-VEGF treatment was not associated with an increase in MACEs.

Add or change institution